Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis

Leukemia. 2006 Jun;20(6):987-93. doi: 10.1038/sj.leu.2404218.

Abstract

AML1-ETO, a leukemia-associated fusion protein generated by the frequently occurred chromosome translocation t(8;21) in acute myeloid leukemia, was shown to exert dichotomous functions in leukemic cells, that is, growth arrest versus differentiation block. By the analysis of oligonucleotide microarray, AML1-ETO was shown to modulate the expressions of an impressive array of pro- and anti-apoptotic genes. Here, we investigate potential effects of the ecdysone inducible AML1-ETO expression on apoptosis of leukemic U937 cell line. We show that AML1-ETO significantly stabilizes death receptor Fas protein and increases proapoptotic Bak in addition to reducing Bcl-2 expression. Accordingly, inducible AML1-ETO expression is followed by apoptosis to a lower degree. Especially, AML1-ETO endows leukemic cells with the susceptibility to anti-Fas agonist antibody, ultraviolet light and camptothecin analog NSC606985-induced apoptosis with increased activation of caspase-3/8. Considering that apoptosis-enhancing effect of AML1-ETO would not be favorable to the leukemogenesis harboring the t(8;21) translocation, it must be overcome to fulfill their leukemogenic potential. Complementary to this prediction is that two AML1-ETO-carrying leukemic cells, Kasumi-1 and SKNO-1, present similar sensitivity to apoptosis induction with AML1-ETO-negative leukemic cells. Therefore, genetic and/or epigenetic screenings of apoptosis-related genes modulated by AML1-ETO deserve to be explored for understanding the mechanisms of AML1-ETO-induced leukemogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Apoptosis / radiation effects
  • Blotting, Western
  • Camptothecin / analogs & derivatives
  • Camptothecin / pharmacology
  • Cell Line, Tumor
  • Core Binding Factor Alpha 2 Subunit / drug effects
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • Core Binding Factor Alpha 2 Subunit / metabolism
  • Cycloheximide / pharmacology
  • Ecdysterone / analogs & derivatives
  • Ecdysterone / pharmacology
  • Flow Cytometry
  • Gene Expression Profiling
  • Gene Expression Regulation, Leukemic / drug effects
  • Humans
  • Oncogene Proteins, Fusion / drug effects
  • Oncogene Proteins, Fusion / genetics*
  • Oncogene Proteins, Fusion / metabolism
  • RNA, Messenger / genetics
  • RUNX1 Translocation Partner 1 Protein
  • Receptors, Tumor Necrosis Factor / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Time Factors
  • Ultraviolet Rays
  • fas Receptor

Substances

  • AML1-ETO fusion protein, human
  • Antibodies, Monoclonal
  • Core Binding Factor Alpha 2 Subunit
  • FAS protein, human
  • NSC606985
  • Oncogene Proteins, Fusion
  • RNA, Messenger
  • RUNX1 Translocation Partner 1 Protein
  • Receptors, Tumor Necrosis Factor
  • fas Receptor
  • Ecdysterone
  • ponasterone A
  • Cycloheximide
  • Camptothecin